Jefferies Financial Group Inc. Reduces Position in Illumina, Inc. $ILMN

Jefferies Financial Group Inc. trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 8.4% during the second quarter, Holdings Channel.com reports. The firm owned 60,000 shares of the life sciences company’s stock after selling 5,500 shares during the period. Jefferies Financial Group Inc.’s holdings in Illumina were worth $5,725,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Cetera Investment Advisers raised its stake in Illumina by 13.7% in the first quarter. Cetera Investment Advisers now owns 26,280 shares of the life sciences company’s stock valued at $2,085,000 after buying an additional 3,173 shares in the last quarter. HB Wealth Management LLC boosted its position in shares of Illumina by 11.7% during the 1st quarter. HB Wealth Management LLC now owns 4,029 shares of the life sciences company’s stock worth $320,000 after acquiring an additional 421 shares in the last quarter. TD Asset Management Inc increased its holdings in shares of Illumina by 0.6% in the 1st quarter. TD Asset Management Inc now owns 50,668 shares of the life sciences company’s stock valued at $4,020,000 after acquiring an additional 314 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Illumina by 4.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 199,176 shares of the life sciences company’s stock worth $15,803,000 after acquiring an additional 9,252 shares in the last quarter. Finally, LPL Financial LLC lifted its stake in Illumina by 10.5% during the first quarter. LPL Financial LLC now owns 91,606 shares of the life sciences company’s stock worth $7,268,000 after purchasing an additional 8,739 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling

In related news, Director Scott Gottlieb acquired 500 shares of Illumina stock in a transaction on Monday, November 3rd. The stock was purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the purchase, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.60% of the stock is currently owned by corporate insiders.

Illumina Stock Up 1.7%

ILMN stock opened at $125.96 on Tuesday. The company has a fifty day moving average price of $105.72 and a 200 day moving average price of $98.01. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $153.06. The company has a market cap of $19.25 billion, a price-to-earnings ratio of 15.94, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the firm posted $1.14 EPS. Illumina’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Sell-side analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have commented on ILMN. Cowen reiterated a “hold” rating on shares of Illumina in a research note on Friday, October 31st. Canaccord Genuity Group upped their target price on shares of Illumina from $105.00 to $112.00 and gave the company a “hold” rating in a report on Friday, October 31st. Barclays lifted their price target on shares of Illumina from $95.00 to $100.00 and gave the stock an “underweight” rating in a research note on Friday, October 31st. Daiwa Capital Markets cut shares of Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price target for the company. in a research report on Tuesday, August 12th. Finally, Robert W. Baird set a $109.00 price objective on Illumina in a report on Friday, October 31st. Five analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $115.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.